Genocea Biosciences Inc (GNCA) Quarterly Balance Sheets

Quarterly · GAAP · USD millions
Access GNCA Annual Balance Sheets →
From Genocea Biosciences Inc through Mar 31 2021, shifts in Mar 31 2022's assets and liabilities provide insight into the company's capital structure and financial stability.
Quarterly Report, GAAP in USD millions
ITEM
(Mar 31 2022)
(Dec 31 2021) (Sep 30 2021) (Jun 30 2021) (Mar 31 2021)
Assets
Cash & cash equivalent20.14
Cash & Short-term Investments20.00
Prepaid Expense And Other Assets Current4.27
Total Current Assets24.41
Equipment/Property/Plant Net6.56
Long-term investments0.63
Other Assets, Noncurrent7.19
Total Assets38.79
Liabilities
Accounts Payable, Current AC0.59
Long-term Debt, Current Maturities LO4.70
Other Liabilities, Current12.74
Total Current Liabilities18.03
Long-term debt2.95
Total Long-term Debt2.95
Derivative Liability, Noncurrent DE0.00
Other liabilities, Noncurrent5.43
Accrued Expenses And Other Current Liabilities8.76
Warrant Liability Noncurrent0.00
Total Liabilities26.40
Stockholders' Equity
Common Stock Value225.06
Additional Paid In Capital Common Stock436.17
Retained Earnings / Accumulated Deficit-423.84
Other Equity-225.00
Common Stockholder's Equity12.39
Preferred Stockholder's Equity0.00
Total Stockholder's Equity12.39
Liabilities & Stockholder's Equity38.79
4 historic quarters locked

Sign in to unlock the full Genocea Biosciences Inc balance sheet history.

About Genocea Biosciences Inc Quarterly Balance Sheet

What this statement shows

This page presents issuer-reported balance sheet data, detailing assets, liabilities, and stockholders equity as reported in SEC filings and standardized by CSIMarket. The balance sheet reflects the company's financial position at the end of each reporting period.

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings - XBRL extraction - balance-sheet normalization in the CSIMarket.com financial database.
  • Accession: 0001457612-22-000054

Balance sheet figures represent financial position at specific reporting dates and may be revised in subsequent filings.